Index O
- Obesity 603-605, 604t
- atherosclerosis and 851
- breast cancer and 1218
- in lipoprotein disorders 607
- morbid, hospitalization and 99
- screening for 47t
- Obsessions 347
- Obsessive-compulsive disorder 326
- Obstructive sleep apnea 460-461
- Occipital lobe, infarction in 1308
- Occupational therapy 287-295
- assessment for 287-290
- interventions for 290-295, 291t
- in parkinsonism 437
- settings for 291t-292t
- Octreotide
- in diarrhea 1091t
- in postprandial hypotension 849
- in Zollinger-Ellison syndrome 1049
- Oculopharyngeal muscular dystrophy 533
- Ofloxacin 1372t
- Ogilvie's syndrome 1116
- colonscopy in 1011
- Ointment 1244t
- Olanzapine 332-333
- in dementia-related behavior disorders 376
- Older Americans Act (1965) 169
- Olecranon bursitis 498
- Olfaction, dysfunction of 1025-1027, 1347
- Olivopontocerebellar atrophy 442
- Olmesartan
- in hypertension 842t
- Olsalazine
- in Crohn's disease 1064, 1064t
- in ulcerative colitis 1061t
- Omega-3 fatty acids 619t, 622
- Omeprazole
- in esophagitis 1112
- in peptic ulcer disease 1046
- warfarin interaction with 68t
- in Zollinger-Ellison syndrome 1049
- Oncogenes, leukemia and 725
- Ondansetron
- with chemotherapy 719
- Onychogryphosis 1235
- Onycholysis 1261
- Onychomycosis 1261
- Oophorectomy, sexual activity after 1162
- Ophidiophobia 327
- Ophthalmic artery, inflammation of 507-508
- Ophthalmic nerve, herpes zoster infection of 1259-1260
- Ophthalmologic disorders (see Eyes; Vision)
- Opioids 387t, 390-393
- addiction to 393
- adverse effects of 341, 391-392
- in cancer patient 722
- confusion with 391
- constipation with 392
- delirium with 352t
- dependence on 392
- in diarrhea 1091t
- in diverticular disease 1055t
- in dying patient 117
- fall risk and 197t
- nausea with 392
- in osteoarthritis 493
- patient-controlled administration of 391
- tolerance to 392
- urinary incontinence with 967t
- vertigo with 392
- Oprelvekin 719
- Optic nerve
- ethambutol-induced inflammation of 1374t
- ischemia of 1307
- Oral cancer 1021-1023
- screening for 718t
- Orbicular muscles
- Orbit 1289
- Orchiectomy
- in prostate cancer 1186
- sexual activity after 1162
- Organ donation 125
- Orgasmic disorder, in women 1178
- Oriental cholangitis 1126-1127
- Orientation 348
- Orlistat 605, 636
- Oropharynx
- bacterial colonization of 759
- cancer of 1021-1023
- Orthostatic hypotension XXX, 845-848, 846t (see also Hypotension, orthostatic)
- Oseltamivir 770, 1377t
- Osler nodes 880
- Osler's sign 823, 836
- Osmolality
- in hyponatremia 565
- Osmotic demyelination syndrome 565
- Osmotic gap, in diarrhea 1090
- Osteitis deformans 480-483
- Osteitis fibrosa cystica 576
- Osteoarthritis 489-493, 492t
- of hand 538
- occupational therapy for 290
- prevention of 51t
- sexual activity and 1160
- Osteoarthropathy, hypertrophic, cervical 1037
- dysphagia in 1032, 1033
- Osteoblasts
- bone loss and469t
- in bone regeneration 468
- Osteomalacia 483-486
- muscular disorders in 530-531
- Osteomyelitis 486-487
- Osteopenia 467, 472
- adverse drug interactions with 67t
- Osteoporosis 467-468, 472-480, 1210
- bed rest effects on 103
- evaluation of 476-477
- genetic factors in 475
- in male hypogonadism 1173
- pathogenesis of 469t, 473
- prevention of 51, 51t, 478-480
- resources on 1416
- risk factors for 474-475
- screening for 47t
- secondary 473, 474f
- Osteoporosis circumscripta 482
- Otalgia 1333-1334
- Otitis
- external 1330t, 1335-1336
- middle (otitis media)
- serous (secretory) 1330t, 1336-1337
- suppurative 1337-1338
- Otomycosis 1335, 1336
- Otosclerosis 1339-1340
- tinnitus and 1330t
- Otoscopy 1319
- Ovary, cancer of 1204, 1205t
- estrogen replacement therapy and 1214
- screening for 718t
- Overlap syndromes 527
- Overuse syndrome 535, 540
- Oxacillin 1367t-1368t
- in infective endocarditis 883t
- Oxaprozin 386t, 492t
- Oxazepam
- adverse effects of 64t
- in generalized anxiety disorder 324
- Oxoglutarate 603
- Oxybutynin
- adverse effects of 64t
- in detrusor overactivity 976, 977t
- Oxycodone 387t
- Oxygen
- arterial, partial pressure of (Pao2)
- age-related changes in 756
- in pulmonary embolism 776
- in respiratory failure 788
- cardiac consumption of 816t
- maximal consumption of (VO2max) 756-757
- therapy with
- in COPD 785, 786, 787
- in respiratory failure 790
- Oxymetazoline 1346
- Oxymorphone 387t
- Oxyphenbutazone, sexual function and 1164t
- Oxytetracycline 1373t
|
 |
|
|
|
